Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02571777




Registration number
NCT02571777
Ethics application status
Date submitted
5/10/2015
Date registered
8/10/2015
Date last updated
22/07/2020

Titles & IDs
Public title
Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma
Scientific title
A Multicenter, Randomized, 52-week, Double-blind, Parallelgroup, Active Controlled Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma
Secondary ID [1] 0 0
2015-002899-25
Secondary ID [2] 0 0
CQVM149B2302
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Condition category
Condition code
Respiratory 0 0 0 0
Asthma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - QVM149 150/50/160
Treatment: Drugs - QVM149 150/50/80
Treatment: Drugs - QMF149 150/320
Treatment: Drugs - QMF149 150/160
Treatment: Drugs - salmeterol/fluticasone

Experimental: QVM149 150/50/160 µg o.d. - QVM149 150/50/160 µg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device

Experimental: QVM149 150/50/80 µg o.d. - QVM149 150/50/80 µg (indacaterol acetate/glycopyrronium/mometasone furoate) once daily (o.d.) delivered via Concept1 device

Active Comparator: QMF149 150/320 µg o.d. - QMF149 150/320 µg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device

Active Comparator: QMF149 150/160 µg o.d. - QMF149 150/160 µg (indacaterol acetate/mometasone furoate) once daily (o.d.) delivered via Concept1 device

Active Comparator: Salmeterol/fluticasone 50/500 µg b.i.d. - Salmeterol xinafoate /fluticasone propionate 50/500 µg twice daily (b.i.d.) delivered via Accuhaler®


Treatment: Drugs: QVM149 150/50/160


Treatment: Drugs: QVM149 150/50/80


Treatment: Drugs: QMF149 150/320


Treatment: Drugs: QMF149 150/160


Treatment: Drugs: salmeterol/fluticasone
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Trough Forced Expiratory Volume in 1 Second (Trough FEV1) of QVM149 Versus QMF149 at Week 26
Timepoint [1] 0 0
26 weeks
Secondary outcome [1] 0 0
Asthma Control Questionnaire (ACQ-7) at Week 26 and Week 52
Timepoint [1] 0 0
26 weeks, 52 weeks
Secondary outcome [2] 0 0
Trough Forced Expiratory Volume in 1 Second (Trough FEV1) of QVM149 Versus Salmeterol/Fluticasone at Week 26
Timepoint [2] 0 0
26 weeks
Secondary outcome [3] 0 0
Trough FEV1 at Week 52
Timepoint [3] 0 0
52 weeks
Secondary outcome [4] 0 0
Pre-dose Forced Vital Capacity (FVC) at Week 4 and Week 12
Timepoint [4] 0 0
4 weeks, 12 weeks
Secondary outcome [5] 0 0
Trough Forced Expiratory Flow (FEF) Between 25% and 75% of FVC (FEF25-75) at 52 Weeks
Timepoint [5] 0 0
Up to Week 52
Secondary outcome [6] 0 0
Change From Baseline in Morning and Evening Peak Expiratory Flow Rate (PEF) Over 26 and 52 Weeks of Treatment
Timepoint [6] 0 0
Baseline, 26 weeks, 52 weeks
Secondary outcome [7] 0 0
Change From Baseline in Percentage of Asthma Symptom-free Days Over 52 Weeks
Timepoint [7] 0 0
Baseline, 52 weeks
Secondary outcome [8] 0 0
Change From Baseline in Percentage of Days With no Daytime Symptoms Over 52 Weeks
Timepoint [8] 0 0
Baseline, 52 weeks
Secondary outcome [9] 0 0
Change From Baseline in Percentage of Nights With no Night-time Awakenings Over 52 Weeks
Timepoint [9] 0 0
Baseline, 52 weeks
Secondary outcome [10] 0 0
Change From Baseline in Percentage of Mornings With no Symptoms on Rising Over 52 Weeks
Timepoint [10] 0 0
Baseline, 52 weeks
Secondary outcome [11] 0 0
Change From Baseline in Percentage of Days Without Rescue Medication Use Over 26 and 52 Weeks
Timepoint [11] 0 0
Baseline, 26 weeks, 52 weeks
Secondary outcome [12] 0 0
Percentage of Patients Achieving the Minimal Clinically Important Difference (MCID) ACQ = 0.5 at Week 26 and Week 52
Timepoint [12] 0 0
26 weeks, 52 weeks
Secondary outcome [13] 0 0
Time to First Hospitalization for Asthma Exacerbation
Timepoint [13] 0 0
52 weeks on average, up to 416 days
Secondary outcome [14] 0 0
Time to First Asthma Exacerbation by Exacerbation Category
Timepoint [14] 0 0
52 weeks on average, up to 416 days
Secondary outcome [15] 0 0
Annual Rate of Asthma Exacerbations by Exacerbation Category
Timepoint [15] 0 0
52 weeks
Secondary outcome [16] 0 0
Duration in Days of Asthma Exacerbations by Exacerbation Category
Timepoint [16] 0 0
Up to Week 52
Secondary outcome [17] 0 0
Percentage of Participants With at Least One Asthma Exacerbation by Exacerbation Category
Timepoint [17] 0 0
Up to Week 52
Secondary outcome [18] 0 0
Time in Days to Permanent Discontinuation of Study Medication Due to Asthma Exacerbation
Timepoint [18] 0 0
52 weeks on average, up to 416 days
Secondary outcome [19] 0 0
Total Amount of Oral Corticosteroid Used (in Prednisone-equivalent mg Doses) to Treat Asthma Exacerbations
Timepoint [19] 0 0
Up to Week 52
Secondary outcome [20] 0 0
Change From Baseline in Percentage of Rescue Medication Free Days Over 26 and 52 Weeks
Timepoint [20] 0 0
Baseline, 26 weeks, 52 weeks
Secondary outcome [21] 0 0
Asthma Quality of Life Questionnaire (AQLQ) at Week 52
Timepoint [21] 0 0
52 weeks
Secondary outcome [22] 0 0
Pre-dose FEV1 at Weeks 4 and 12
Timepoint [22] 0 0
4 weeks, 12 weeks
Secondary outcome [23] 0 0
Percentage of Participants With Composite Endpoint of Serious Asthma Outcomes
Timepoint [23] 0 0
Up to Week 52

Eligibility
Key inclusion criteria
* Patients with a diagnosis of asthma, (GINA 2015) for a period of at least 1 year prior to Visit 1 (Screening).
* Patients who have used medium or high dose of ICS/LABA combinations for asthma for at least 3 months and at stable medium or high doses of ICS/LABA for at least 1 month prior to Visit 1.
* Patients must be symptomatic at screening despite treatment with mid or high stable doses of ICS/LABA. Patients with ACQ-7 score = 1.5 at Visit 101 and at Visit 102 (before randomization).
* Patients with documented history of at least one asthma exacerbation which required medical care from a physician, ER visit (or local equivalent structure) or hospitalization in the 12 months prior to Visit 1, and required systemic corticosteroid treatment.
* Pre-bronchodilator FEV1 of < 80 % of the predicted normal value for the patient according to ATS/ERS guidelines after withholding bronchodilators at both visits 101 and 102.
* Withholding period of bronchodilators prior to spirometry: SABA for = 6 hrs, Twice daily LABA (or FDC of ICS/LABA) for = 12 hrs, Once daily LABA (or FDC of ICS/LABA) for = 24 hrs, SAMA for = 8 hrs, Short acting xanthines for 12 hrs, Long acting xanthines for 24 hrs, .
* Washout period of each drug should be kept as close as possible as above and should not be longer. If longer washout period is needed due to scheduling issues, please contact Novartis Medical monitor.
* A one-time repeat of percentage predicated FEV1 (Pre-bronchodilator) at Visit 101 and/or Visit 102 is allowed in an ad-hoc visit. Repeat of Visit 101 spirometry should be done in an ad-hoc visit to be scheduled on a date that would provide sufficient time to receive confirmation from the spirometry data central reviewer of the validity of the assessment before randomization. Run-in medication should be dispensed once spirometry assessment met inclusion criteria (ATS/ERS quality criteria, FEV1 % predicted normal value, and reversibility) as per equipment
* A one-time rescreen is allowed in case the patient fails to meet the criteria at the repeat, provided the patient returned to the required treatment as per inclusion criteria 4
* Patients who demonstrate an increase in FEV1 of 12% and 200 mL within 30 minutes after administration of 400 µg salbutamol/360 µg albuterol (or equivalent dose) at Visit 101.All patients must perform a reversibility test at Visit 101. If reversibility is not demonstrated at Visit 101 then one of the following criteria need to be met.
* Reversibility should be repeated once.
* Patients may be permitted to enter the study with historical evidence of reversibility that was performed according to ATS/ERS guidelines within 2 years prior to Visit 1.
* Alternatively, patients may be permitted to enter the study with a historical positive bronchoprovocation test that was performed within 2 years prior to Visit 1. If reversibility is not demonstrated at Visit 101 (or after repeated assessment in an ad-hoc visit) and historical evidence of reversibility/bronchoprovocation is not available (or was not performed according to the ATS/ERS guidelines patients must be screen failed
* Spacer devices are permitted during reversibility testing only. The Investigator or delegate may decide whether or not to use a spacer for the reversibility testing
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Patients who have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6 weeks of Visit 1 (Screening). If patients experience an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit between Visit 1 and Visit 102 they may be re-screened 6 weeks after recovery from the exacerbation.
* Patients who have ever required intubation for a severe asthma attack/exacerbation.
* Patients who have a clinical condition which is likely to be worsened by ICS administration (e.g. glaucoma, cataract and fragility fractures) who are according to investigator's medical judgment at risk participating in the study.
* Patients treated with a LAMA for asthma within 3 months prior Visit 1 (Screening).
* Patients with narrow-angle glaucoma, symptomatic benign prostatic hyperplasia (BPH) or bladder-neck obstruction or severe renal impairment or urinary retention. BPH patients who are stable on treatment can be considered).
* Patients who have had a respiratory tract infection or asthma worsening as determined by investigator within 4 weeks prior to Visit 1 (Screening) or between Visit 1 and Visit 102. Patients may be re-screened 4 weeks after recovery from their respiratory tract infection or asthma worsening.
* Patients with evidence upon visual inspection (laboratory culture is not required) of clinically significant (in the opinion of investigator) oropharyngeal candidiasis at Visit 102 or earlier, with or without treatment. Patients may be re-screened once their candidiasis has been treated and has resolved.
* Patients with any chronic conditions affecting the upper respiratory tract (e.g. chronic sinusitis) which in the opinion of the investigator may interfere with the study evaluation or optimal participation in the study.
* Patients with a history of chronic lung diseases other than asthma, including (but not limited to) chronic obstructive pulmonary disease, sarcoidosis, interstitial lung disease, cystic fibrosis, clinically significant bronchiectasis and active tuberculosis.
* Patients with Type I diabetes or uncontrolled Type II diabetes.
* Patients who, either in the judgment of the investigator or the responsible Novartis personnel, have a clinically significant condition such as (but not limited to) unstable ischemic heart disease, New York Heart Association (NYHA) Class III/IV left ventricular failure arrhythmia, uncontrolled hypertension, cerebrovascular disease, psychiatric disease, neurodegenerative diseases, or other neurological disease, uncontrolled hypo- and hyperthyroidism and other autoimmune diseases, hypokalemia, hyperadrenergic state, or ophthalmologic disorder or patients with a medical condition that might compromise patient safety or compliance, interfere with evaluation, or preclude completion of the study.
* Patients with paroxysmal (e.g., intermittent) atrial fibrillation are excluded. Patients with persistent atrial fibrillation as defined by continuous atrial fibrillation for at least 6 months and controlled with a rate control strategy (i.e., selective beta blockers, calcium channel blocker, pacemaker placement, digoxin or ablation therapy) for at least 6 months may be considered for inclusion. In such patients, atrial fibrillation must be present at the run-in visit (Visit 101) with a resting ventricular rate < 100/min. At Visit 101 the atrial fibrillation must be confirmed by central reading.
* Patients with a history of myocardial infarction (this should be confirmed clinically by the investigator) within the previous 12 months.
* Concomitant use of agents known to prolong the QT interval unless it can be permanently discontinued for the duration of study
* Patients with a history of long QT syndrome or whose QTc measured at Visit 101 (Fridericia method) is prolonged (> 450 msec for males and > 460 msec for females) and confirmed by a central assessor (these patients should not be rescreened).
* Patients with a history of hypersensitivity to lactose, any of the study drugs or to similar drugs within the class including untoward reactions to sympathomimetic amines or inhaled medication or any component thereof.
* Patients who have not achieved an acceptable spirometry result at Visit 101 in accordance with ATS/ERS criteria for acceptability and repeatability. A one-time repeat spirometry is allowed in an ad-hoc visit scheduled as close as possible from the first attempt (but not on the same day) if the spirometry did not qualify due to ATS/ERS criteria at Visit 101 and/or Visit 102. If the patient fails the repeat assessment, the patient may be rescreened once, provided the patient returns to the required treatment as per inclusion criteria 4.
* Patients unable to use the Concept1 dry powder inhaler, Accuhaler or a metered dose inhaler. Spacer devices are not permitted.
* History of alcohol or other substance abuse.
* Patients with a known history of non-compliance to medication or who were unable or unwilling to complete a patient diary or who are unable or unwilling to use Electronic Peak Flow with e-diary device.
* Patients who do not maintain regular day/night, waking/sleeping cycles (e.g., night shift workers).

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
8/12/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
14/06/2019
Sample size
Target
Accrual to date
Final
3092
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
Argentina
State/province [1] 0 0
Buenos Aires
Country [2] 0 0
Argentina
State/province [2] 0 0
Cordoba
Country [3] 0 0
Argentina
State/province [3] 0 0
Entre Rios
Country [4] 0 0
Argentina
State/province [4] 0 0
Mendoza
Country [5] 0 0
Argentina
State/province [5] 0 0
Rosario
Country [6] 0 0
Argentina
State/province [6] 0 0
Santa Fe
Country [7] 0 0
Argentina
State/province [7] 0 0
Tucuman
Country [8] 0 0
Argentina
State/province [8] 0 0
Parana
Country [9] 0 0
Austria
State/province [9] 0 0
Bludenz
Country [10] 0 0
Austria
State/province [10] 0 0
Feldbach
Country [11] 0 0
Austria
State/province [11] 0 0
Feldkirch
Country [12] 0 0
Austria
State/province [12] 0 0
Grieskirchen
Country [13] 0 0
Belgium
State/province [13] 0 0
BEL
Country [14] 0 0
Belgium
State/province [14] 0 0
Brussel
Country [15] 0 0
Belgium
State/province [15] 0 0
Braine L Alleud Waterloo
Country [16] 0 0
Belgium
State/province [16] 0 0
Bruxelles
Country [17] 0 0
Belgium
State/province [17] 0 0
Eghezee
Country [18] 0 0
Belgium
State/province [18] 0 0
Erpent
Country [19] 0 0
Belgium
State/province [19] 0 0
Lebbeke
Country [20] 0 0
Belgium
State/province [20] 0 0
Liege
Country [21] 0 0
Belgium
State/province [21] 0 0
Malmedy
Country [22] 0 0
Bulgaria
State/province [22] 0 0
BGR
Country [23] 0 0
Bulgaria
State/province [23] 0 0
Ruse
Country [24] 0 0
Bulgaria
State/province [24] 0 0
Sofia
Country [25] 0 0
Bulgaria
State/province [25] 0 0
Stara Zagora
Country [26] 0 0
Canada
State/province [26] 0 0
Alberta
Country [27] 0 0
Canada
State/province [27] 0 0
Ontario
Country [28] 0 0
Canada
State/province [28] 0 0
Quebec
Country [29] 0 0
Chile
State/province [29] 0 0
Region Metropolitana
Country [30] 0 0
Chile
State/province [30] 0 0
TX
Country [31] 0 0
Chile
State/province [31] 0 0
VII Region Del Maule
Country [32] 0 0
Chile
State/province [32] 0 0
Santiago
Country [33] 0 0
China
State/province [33] 0 0
Hainan
Country [34] 0 0
China
State/province [34] 0 0
Jiangsu
Country [35] 0 0
China
State/province [35] 0 0
Jilin
Country [36] 0 0
China
State/province [36] 0 0
Liaoning
Country [37] 0 0
China
State/province [37] 0 0
Shanghai
Country [38] 0 0
China
State/province [38] 0 0
Shanxi
Country [39] 0 0
China
State/province [39] 0 0
Sichuan
Country [40] 0 0
China
State/province [40] 0 0
Chongqing
Country [41] 0 0
China
State/province [41] 0 0
Tianjin
Country [42] 0 0
Colombia
State/province [42] 0 0
Bogota DC
Country [43] 0 0
Colombia
State/province [43] 0 0
Bogota
Country [44] 0 0
Colombia
State/province [44] 0 0
Floridablanca
Country [45] 0 0
Colombia
State/province [45] 0 0
Medellin
Country [46] 0 0
Croatia
State/province [46] 0 0
HRV
Country [47] 0 0
Croatia
State/province [47] 0 0
Petrinja
Country [48] 0 0
Croatia
State/province [48] 0 0
Zadar
Country [49] 0 0
Croatia
State/province [49] 0 0
Zagreb
Country [50] 0 0
Denmark
State/province [50] 0 0
Copenhagen NV
Country [51] 0 0
Denmark
State/province [51] 0 0
Hvidovre
Country [52] 0 0
Estonia
State/province [52] 0 0
Tallinn
Country [53] 0 0
Estonia
State/province [53] 0 0
Tartu
Country [54] 0 0
Finland
State/province [54] 0 0
Jyvaskyla
Country [55] 0 0
France
State/province [55] 0 0
Herault
Country [56] 0 0
Germany
State/province [56] 0 0
Nordrhein Westfalen
Country [57] 0 0
Germany
State/province [57] 0 0
NRW
Country [58] 0 0
Germany
State/province [58] 0 0
Sachsen
Country [59] 0 0
Germany
State/province [59] 0 0
Schleswig Holstein
Country [60] 0 0
Germany
State/province [60] 0 0
Annaberg-Buchholz
Country [61] 0 0
Germany
State/province [61] 0 0
Aschaffenburg
Country [62] 0 0
Germany
State/province [62] 0 0
Berlin
Country [63] 0 0
Germany
State/province [63] 0 0
Bonn
Country [64] 0 0
Germany
State/province [64] 0 0
Darmstadt
Country [65] 0 0
Germany
State/province [65] 0 0
Frankfurt am Main
Country [66] 0 0
Germany
State/province [66] 0 0
Frankfurt
Country [67] 0 0
Germany
State/province [67] 0 0
Halle
Country [68] 0 0
Germany
State/province [68] 0 0
Hamburg
Country [69] 0 0
Germany
State/province [69] 0 0
Hannover
Country [70] 0 0
Germany
State/province [70] 0 0
Karlsruhe
Country [71] 0 0
Germany
State/province [71] 0 0
Leipzig
Country [72] 0 0
Germany
State/province [72] 0 0
Lübeck
Country [73] 0 0
Germany
State/province [73] 0 0
Mainz
Country [74] 0 0
Germany
State/province [74] 0 0
Mittweida
Country [75] 0 0
Germany
State/province [75] 0 0
Neu Isenburg
Country [76] 0 0
Germany
State/province [76] 0 0
Potsdam
Country [77] 0 0
Germany
State/province [77] 0 0
Rudersdorf
Country [78] 0 0
Germany
State/province [78] 0 0
Witten
Country [79] 0 0
Greece
State/province [79] 0 0
GR
Country [80] 0 0
Greece
State/province [80] 0 0
Athens
Country [81] 0 0
Greece
State/province [81] 0 0
Heraklion Crete
Country [82] 0 0
Hungary
State/province [82] 0 0
HUN
Country [83] 0 0
Hungary
State/province [83] 0 0
Balassagyarmat
Country [84] 0 0
Hungary
State/province [84] 0 0
Budapest
Country [85] 0 0
Hungary
State/province [85] 0 0
Godollo
Country [86] 0 0
Hungary
State/province [86] 0 0
Komarom
Country [87] 0 0
Hungary
State/province [87] 0 0
Mateszalka
Country [88] 0 0
Hungary
State/province [88] 0 0
Nyiregyhaza
Country [89] 0 0
Hungary
State/province [89] 0 0
Szarvas
Country [90] 0 0
Hungary
State/province [90] 0 0
Szeged
Country [91] 0 0
Hungary
State/province [91] 0 0
Szigetszentmiklos
Country [92] 0 0
Hungary
State/province [92] 0 0
Szigetvar
Country [93] 0 0
India
State/province [93] 0 0
Andhra Pradesh
Country [94] 0 0
India
State/province [94] 0 0
Bihar
Country [95] 0 0
India
State/province [95] 0 0
Delhi
Country [96] 0 0
India
State/province [96] 0 0
Gujarat
Country [97] 0 0
India
State/province [97] 0 0
Haryana
Country [98] 0 0
India
State/province [98] 0 0
Karnataka
Country [99] 0 0
India
State/province [99] 0 0
Kerala
Country [100] 0 0
India
State/province [100] 0 0
Maharashtra
Country [101] 0 0
India
State/province [101] 0 0
Maharastra
Country [102] 0 0
India
State/province [102] 0 0
Punjab
Country [103] 0 0
India
State/province [103] 0 0
Rajasthan
Country [104] 0 0
India
State/province [104] 0 0
Tamil Nadu
Country [105] 0 0
India
State/province [105] 0 0
Telangana
Country [106] 0 0
India
State/province [106] 0 0
Uttar Pradesh
Country [107] 0 0
India
State/province [107] 0 0
Uttarakhand
Country [108] 0 0
India
State/province [108] 0 0
West Bengal
Country [109] 0 0
Ireland
State/province [109] 0 0
Cork
Country [110] 0 0
Ireland
State/province [110] 0 0
Dublin
Country [111] 0 0
Israel
State/province [111] 0 0
Ashkelon
Country [112] 0 0
Israel
State/province [112] 0 0
Beer-Sheva
Country [113] 0 0
Israel
State/province [113] 0 0
Jerusalem
Country [114] 0 0
Israel
State/province [114] 0 0
Kfar Saba
Country [115] 0 0
Israel
State/province [115] 0 0
Petach Tikva
Country [116] 0 0
Israel
State/province [116] 0 0
Rehovot
Country [117] 0 0
Israel
State/province [117] 0 0
Tel Giborim, Holon
Country [118] 0 0
Italy
State/province [118] 0 0
BA
Country [119] 0 0
Italy
State/province [119] 0 0
CT
Country [120] 0 0
Italy
State/province [120] 0 0
CZ
Country [121] 0 0
Italy
State/province [121] 0 0
FI
Country [122] 0 0
Italy
State/province [122] 0 0
ME
Country [123] 0 0
Italy
State/province [123] 0 0
VR
Country [124] 0 0
Italy
State/province [124] 0 0
Ancona
Country [125] 0 0
Italy
State/province [125] 0 0
Messina
Country [126] 0 0
Italy
State/province [126] 0 0
Pordenone
Country [127] 0 0
Italy
State/province [127] 0 0
Roma
Country [128] 0 0
Japan
State/province [128] 0 0
Fukuoka
Country [129] 0 0
Japan
State/province [129] 0 0
Hokkaido
Country [130] 0 0
Japan
State/province [130] 0 0
Hyogo
Country [131] 0 0
Japan
State/province [131] 0 0
Ibaraki
Country [132] 0 0
Japan
State/province [132] 0 0
Kanagawa
Country [133] 0 0
Japan
State/province [133] 0 0
Mie
Country [134] 0 0
Japan
State/province [134] 0 0
Miyagi
Country [135] 0 0
Japan
State/province [135] 0 0
Okayama
Country [136] 0 0
Japan
State/province [136] 0 0
Osaka
Country [137] 0 0
Japan
State/province [137] 0 0
Shibuya Ku
Country [138] 0 0
Japan
State/province [138] 0 0
Shizuoka
Country [139] 0 0
Japan
State/province [139] 0 0
Tokyo
Country [140] 0 0
Jordan
State/province [140] 0 0
JOR
Country [141] 0 0
Latvia
State/province [141] 0 0
LVA
Country [142] 0 0
Latvia
State/province [142] 0 0
LV
Country [143] 0 0
Latvia
State/province [143] 0 0
Daugavpils
Country [144] 0 0
Latvia
State/province [144] 0 0
Riga
Country [145] 0 0
Lebanon
State/province [145] 0 0
LBN
Country [146] 0 0
Lebanon
State/province [146] 0 0
Ashrafieh
Country [147] 0 0
Lebanon
State/province [147] 0 0
Beirut
Country [148] 0 0
Lithuania
State/province [148] 0 0
LTU
Country [149] 0 0
Lithuania
State/province [149] 0 0
LT
Country [150] 0 0
Lithuania
State/province [150] 0 0
Kaunas
Country [151] 0 0
Lithuania
State/province [151] 0 0
Klaipeda
Country [152] 0 0
Lithuania
State/province [152] 0 0
Siauliai
Country [153] 0 0
Lithuania
State/province [153] 0 0
Vilnius
Country [154] 0 0
Mexico
State/province [154] 0 0
Jalisco
Country [155] 0 0
Mexico
State/province [155] 0 0
MEX
Country [156] 0 0
Mexico
State/province [156] 0 0
Nuevo Leon
Country [157] 0 0
Mexico
State/province [157] 0 0
Oaxaca
Country [158] 0 0
Mexico
State/province [158] 0 0
Veracruz
Country [159] 0 0
Netherlands
State/province [159] 0 0
CK
Country [160] 0 0
Netherlands
State/province [160] 0 0
Eindhoven
Country [161] 0 0
Netherlands
State/province [161] 0 0
Groningen
Country [162] 0 0
Netherlands
State/province [162] 0 0
Harderwijk
Country [163] 0 0
Netherlands
State/province [163] 0 0
Heerlen
Country [164] 0 0
Netherlands
State/province [164] 0 0
Helmond
Country [165] 0 0
Netherlands
State/province [165] 0 0
Hengelo
Country [166] 0 0
Netherlands
State/province [166] 0 0
Rotterdam
Country [167] 0 0
Netherlands
State/province [167] 0 0
Zutphen
Country [168] 0 0
Peru
State/province [168] 0 0
Lima
Country [169] 0 0
Philippines
State/province [169] 0 0
Batangas
Country [170] 0 0
Philippines
State/province [170] 0 0
Metro Manila
Country [171] 0 0
Philippines
State/province [171] 0 0
Bulacan
Country [172] 0 0
Philippines
State/province [172] 0 0
Manila
Country [173] 0 0
Philippines
State/province [173] 0 0
Quezon City
Country [174] 0 0
Poland
State/province [174] 0 0
POL
Country [175] 0 0
Poland
State/province [175] 0 0
Aleksandrow Odzki
Country [176] 0 0
Poland
State/province [176] 0 0
Bielsko-Biala
Country [177] 0 0
Poland
State/province [177] 0 0
Elblag
Country [178] 0 0
Poland
State/province [178] 0 0
Inowroclaw
Country [179] 0 0
Poland
State/province [179] 0 0
Krakow
Country [180] 0 0
Poland
State/province [180] 0 0
Lodz
Country [181] 0 0
Poland
State/province [181] 0 0
Ostrow Wielkopolski
Country [182] 0 0
Poland
State/province [182] 0 0
Sopot
Country [183] 0 0
Poland
State/province [183] 0 0
Wroclaw
Country [184] 0 0
Poland
State/province [184] 0 0
Zawadzkie
Country [185] 0 0
Portugal
State/province [185] 0 0
Coimbra
Country [186] 0 0
Portugal
State/province [186] 0 0
Lisboa
Country [187] 0 0
Portugal
State/province [187] 0 0
Porto
Country [188] 0 0
Romania
State/province [188] 0 0
ROM
Country [189] 0 0
Romania
State/province [189] 0 0
Timis
Country [190] 0 0
Romania
State/province [190] 0 0
Arad
Country [191] 0 0
Romania
State/province [191] 0 0
Bacau
Country [192] 0 0
Romania
State/province [192] 0 0
Brasov
Country [193] 0 0
Romania
State/province [193] 0 0
Bucharest
Country [194] 0 0
Romania
State/province [194] 0 0
Bucuresti
Country [195] 0 0
Romania
State/province [195] 0 0
Cluj Napoca
Country [196] 0 0
Romania
State/province [196] 0 0
Cluj-Napoca
Country [197] 0 0
Romania
State/province [197] 0 0
Constanta
Country [198] 0 0
Romania
State/province [198] 0 0
Deva
Country [199] 0 0
Romania
State/province [199] 0 0
Pitesti
Country [200] 0 0
Russian Federation
State/province [200] 0 0
Barnaul
Country [201] 0 0
Russian Federation
State/province [201] 0 0
Chelyabinsk
Country [202] 0 0
Russian Federation
State/province [202] 0 0
Ivanovo
Country [203] 0 0
Russian Federation
State/province [203] 0 0
Kazan
Country [204] 0 0
Russian Federation
State/province [204] 0 0
Kemerovo
Country [205] 0 0
Russian Federation
State/province [205] 0 0
Moscow
Country [206] 0 0
Russian Federation
State/province [206] 0 0
Nizhny Novgorod
Country [207] 0 0
Russian Federation
State/province [207] 0 0
Novosibirsk
Country [208] 0 0
Russian Federation
State/province [208] 0 0
Omsk
Country [209] 0 0
Russian Federation
State/province [209] 0 0
Perm
Country [210] 0 0
Russian Federation
State/province [210] 0 0
Pskov
Country [211] 0 0
Russian Federation
State/province [211] 0 0
Pyatigorsk
Country [212] 0 0
Russian Federation
State/province [212] 0 0
Saint Petersburg
Country [213] 0 0
Russian Federation
State/province [213] 0 0
Saint-Petersburg
Country [214] 0 0
Russian Federation
State/province [214] 0 0
Saratov
Country [215] 0 0
Russian Federation
State/province [215] 0 0
Sestroretsk
Country [216] 0 0
Russian Federation
State/province [216] 0 0
Smolensk
Country [217] 0 0
Russian Federation
State/province [217] 0 0
St Petersburg
Country [218] 0 0
Russian Federation
State/province [218] 0 0
St. Petersburg
Country [219] 0 0
Russian Federation
State/province [219] 0 0
Tomsk
Country [220] 0 0
Russian Federation
State/province [220] 0 0
Tver
Country [221] 0 0
Russian Federation
State/province [221] 0 0
Ufa
Country [222] 0 0
Russian Federation
State/province [222] 0 0
Ulyanovsk
Country [223] 0 0
Russian Federation
State/province [223] 0 0
Vladikavkaz
Country [224] 0 0
Russian Federation
State/province [224] 0 0
Volgograd
Country [225] 0 0
Russian Federation
State/province [225] 0 0
Vsevolozhsk
Country [226] 0 0
Russian Federation
State/province [226] 0 0
Yaroslavl
Country [227] 0 0
Slovakia
State/province [227] 0 0
Slovak Republic
Country [228] 0 0
Slovakia
State/province [228] 0 0
Kezmarok
Country [229] 0 0
Slovakia
State/province [229] 0 0
Kosice
Country [230] 0 0
Slovakia
State/province [230] 0 0
Liptovsky Mikulas
Country [231] 0 0
Slovakia
State/province [231] 0 0
Poprad
Country [232] 0 0
Slovakia
State/province [232] 0 0
Presov
Country [233] 0 0
Slovakia
State/province [233] 0 0
Spisska Nova Ves
Country [234] 0 0
Slovakia
State/province [234] 0 0
Trencin
Country [235] 0 0
Slovakia
State/province [235] 0 0
Zilina
Country [236] 0 0
Slovakia
State/province [236] 0 0
Zvolen
Country [237] 0 0
South Africa
State/province [237] 0 0
Durban
Country [238] 0 0
South Africa
State/province [238] 0 0
Kwazulu Natal
Country [239] 0 0
South Africa
State/province [239] 0 0
ZAF
Country [240] 0 0
South Africa
State/province [240] 0 0
Cape Town
Country [241] 0 0
Spain
State/province [241] 0 0
Andalucia
Country [242] 0 0
Spain
State/province [242] 0 0
Barcelona
Country [243] 0 0
Spain
State/province [243] 0 0
Cantabria
Country [244] 0 0
Spain
State/province [244] 0 0
Castellon
Country [245] 0 0
Spain
State/province [245] 0 0
Catalunya
Country [246] 0 0
Spain
State/province [246] 0 0
Comunidad Valenciana
Country [247] 0 0
Spain
State/province [247] 0 0
Extremadura
Country [248] 0 0
Spain
State/province [248] 0 0
Santa Cruz De Tenerife
Country [249] 0 0
Spain
State/province [249] 0 0
Leon
Country [250] 0 0
Spain
State/province [250] 0 0
Zaragoza
Country [251] 0 0
Sweden
State/province [251] 0 0
Lidingo
Country [252] 0 0
Sweden
State/province [252] 0 0
Stockholm
Country [253] 0 0
Switzerland
State/province [253] 0 0
Gossau
Country [254] 0 0
Thailand
State/province [254] 0 0
Nonthaburi
Country [255] 0 0
Thailand
State/province [255] 0 0
THA
Country [256] 0 0
Thailand
State/province [256] 0 0
Bangkok
Country [257] 0 0
Thailand
State/province [257] 0 0
Chiang Mai
Country [258] 0 0
United Kingdom
State/province [258] 0 0
East Yorkshire
Country [259] 0 0
United Kingdom
State/province [259] 0 0
London
Country [260] 0 0
United Kingdom
State/province [260] 0 0
Wiltshire
Country [261] 0 0
Vietnam
State/province [261] 0 0
VNM
Country [262] 0 0
Vietnam
State/province [262] 0 0
Hanoi
Country [263] 0 0
Vietnam
State/province [263] 0 0
Ho Chi Minh

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of the trial was to evaluate the efficacy and safety of two different doses of QVM149 (QVM149 150/50/80 µg and QVM149 150/50/160 µg via Concept1) over two respective QMF149 doses (QMF149 150/160 µg and QMF149 150/320) µg via Concept1 in poorly controlled asthmatics as determined by pulmonary function testing and effects on asthma control.
Trial website
https://clinicaltrials.gov/study/NCT02571777
Trial related presentations / publications
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02571777